Nano Innovation for Cancer (NICE)
At a Glance
- Status: Active Consortium
- Year Launched: 2013
- Initiating Organization: BioAlliance Pharma
- Initiator Type: Industry
- Disease focus:
- Location: Europe
Nano Innovation for Cancer (NICE) is the first consortium of nanomedicine stakeholders in France focused on aspects of characterization and industrialization of processes specific to nanodrugs. The consortium has been accredited by the Medicen Paris Region, a competitive cluster for innovative therapies in Ile-de-France.
The NICE consortium includes partners with deep expertise in the field of nanomedicine. Its mission is to build a platform to accelerate the development and industrialization of nanomedicine in France by capitalizing on the strong and complementary expertise of each partner.
July 2013: Consortium launch
October 2014: Second grant announced
An amount of €4.3 million was allocated directly to BioAlliance Pharma to accelerate the industrial development of Livatag. The second payment of 1.144 k€ from Bpifrance was announced in October 2014 as part as the funding to support the NICE consortium.
Sponsors & Partners
Institut Galien Paris Sud